Lineage Cell Therapeutics, Inc. (LCTX) vs Entrada Therapeutics, Inc. (TRDA)
Lineage Cell Therapeutics, Inc. and Entrada Therapeutics, Inc. are both Biotechnology companies. Lineage Cell Therapeutics, Inc. and Entrada Therapeutics, Inc. are of similar size ($242.2M and $239.7M). Lineage Cell Therapeutics, Inc. grew revenue faster over the last twelve months: 19.9% against −94.1%. Lineage Cell Therapeutics, Inc. has the higher net margin (−246.6% vs −3,537.7%) and the higher return on invested capital (−186.8% vs −1,060.2%). Across the 17 metrics below, Lineage Cell Therapeutics, Inc. leads on 10 and Entrada Therapeutics, Inc. on 7.
Valuation
Profitability
| Metric | LCTX | TRDA | Biotechnology median |
|---|---|---|---|
| Gross margin | 99.46% | 100.00% | 65.16% |
| Operating margin | (205.23%) | (3,767.07%) | 0.00% |
| Net margin | (246.58%) | (3,537.73%) | 0.00% |
| Free cash flow margin | (186.43%) | (2,867.07%) | 0.00% |
| Return on equity | (60.35%) | (54.09%) | (57.72%) |
| Return on assets | (32.75%) | (44.35%) | (49.22%) |
| Return on invested capital | (186.79%) | (1,060.24%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack